STAT3-IN-15 |
| Catalog No.GC71187 |
STAT3-IN-15 es un potente inhibidor de STAT3 activo por vía oral contra la fibrosis pulmonar idiopática (FPI).
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
STAT3-IN-15 (compound 10k) inhibits NIH-3T3 cell proliferation with an IC50 of 0.47 μM[1].
STAT3-IN-15 forms hydrogen bonds with Lys591 and Ser636, occupying the pY subpocket of STAT3[1].
STAT3-IN-15 (0-100 nM, 72 h) inhibits fibroblast activation and proliferation[1].
STAT3-IN-15 (50 nM, 24 h) inhibited TGF-β1 (5 ng/mL)-induced activation of NIH-3T3 cells[1].
STAT3-IN-15 (200 nM, 24 h) blocks TGF-β1 induced EMT process in A549 cells, determined by morphological changes[1].
STAT3-IN-15 (compound 10k) (30 and 60 mg/kg, intragastric administration) alleviates Bleomycin.html" class="link-product" target="_blank"> Bleomycin -induced pulmonary fibrosis in mouse[1].
References:
[1]. Wang Y, et al. Discovery of the novel Benzo[b]thiophene 1,1-dioxide derivatives as a potent STAT3 inhibitor against idiopathic pulmonary fibrosis. Eur J Med Chem. 2022 Nov 28;246:114953.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *